

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

**VOLUNTARY ANNOUNCEMENT**

**RECEIPT OF US\$25 MILLION RESEARCH AND  
DEVELOPMENT MILESTONE PAYMENT UNDER  
THE STRATEGIC COLLABORATION AND LICENSE AGREEMENT  
WITH ASTRAZENECA**

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 30 January 2026 in relation to the entering into of the strategic collaboration and license agreement (the “**Agreement**”) between the Group and AstraZeneca (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, the Group entered into the Agreement with AstraZeneca to develop innovative long-acting peptide medicines, utilising the Group’s proprietary sustained-release delivery technology platform and AI-driven peptide drug discovery platform.

The Board is pleased to announce that, following the receipt of the upfront payment under the Agreement on 29 May 2026, the Group has received a research and development milestone payment of US\$25 million from AstraZeneca on 10 July 2026. The achievement of this milestone indicates that the relevant research and development work under the Agreement is progressing steadily as planned.

**The development, manufacturing and commercialisation of the relevant licensed products are subject to uncertainties. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. The Company will make further announcement(s) as and when appropriate to disclose material developments in relation to the Agreement.**

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 10 July 2026

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*